TOWA Pharmaceutical CoFRA:6QC -3.92%87 FCF Margin % is 17.33% as of Mar. 2026, which is 842% above its 10-year median of 1.84. GuruFocus rates FRA:6QC with a GF Score™ of 87/100 and a GF Value™ of €17.85 (Fairly Valued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, TOWA Pharmaceutical Co ranks worse than 50.63% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TOWA Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where TOWA Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TOWA Pharmaceutical Co (FRA:6QC) has a FCF Margin % of 17.33% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TOWA Pharmaceutical Co and its competitors. This is 842% above median its historical median of 1.84. According to the industry distribution chart, TOWA Pharmaceutical Co ranks #485 out of 958 companies in the Drug Manufacturers industry, placing it in the top 50.6%.
Is TOWA Pharmaceutical Co's FCF Margin % too high?
TOWA Pharmaceutical Co's current FCF Margin % of 17.33% is 842% above median its 10-year median of 1.84. The Drug Manufacturers industry median FCF Margin % is 2.45. TOWA Pharmaceutical Co's value of 17.33% is 608.8% above this industry median. Based on the distribution chart, TOWA Pharmaceutical Co ranks #485 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TOWA Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TOWA Pharmaceutical Co ranks #485 out of 958 companies for FCF Margin %. This places TOWA Pharmaceutical Co in the lower half of its industry. The industry median FCF Margin % is 2.45. TOWA Pharmaceutical Co's value of 17.33% is 608.8% above this benchmark. While the company's 10-year median is 1.84 vs. the industry median of 2.45, TOWA Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TOWA Pharmaceutical Co's current FCF Margin % of 17.33% is 608.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TOWA Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TOWA Pharmaceutical Co's current FCF Margin % is 17.33%, which is 842% above median its own 10-year median of 1.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (FRA:6QC) is currently considered Fairly Valued. The stock's GF Value™ is €17.85, compared to a current price of €19.60 — trading 9.8% above its estimated fair value. The current FCF Margin % is 17.33%, which is 842% above median its 10-year median of 1.84 and 608.8% above the Drug Manufacturers industry median of 2.45. TOWA Pharmaceutical Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For TOWA Pharmaceutical Co (FRA:6QC), the current FCF Margin % is 17.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TOWA Pharmaceutical Co (FRA:6QC) Overvalued in 2026?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued.
The current stock price of €19.60 is trading 9.8% above its estimated GF Value™ of €17.85.
GuruFocus considers TOWA Pharmaceutical Co to be Fairly Valued.
Key valuation signals for FRA:6QC:
FCF Margin %: 17.33% (842% above median its 10-year median of 1.84)
GF Value™: €17.85 vs. price of €19.60 (9.8% above fair value)
Industry Position: 608.8% above the Drug Manufacturers median (#485 of 958)
No single metric tells the full story. See the FRA:6QC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
87GF Score
Get the complete analysis for FRA:6QC
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6QC has been successfully added to your 
